High materiality9/10
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
Why it may matterVerify against the original reporting
Strong earnings growth and positive guidance suggest solid financial health.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
GeneDx reports a Q3 EPS loss of $(0.31), beating expectations. Sales surged 44% to $76.87 million, exceeding $64.99 million consensus. Exome and genome tests revenue grew 77% year-over-year to $60 million. Adjusted net income hits $1.2 million, improving 143% sequentially. 2024 revenue guidance raised to $284-$290 million, surpassing previous estimates.
- GeneDx reports a Q3 EPS loss of $(0.31), beating expectations.
- Sales surged 44% to $76.87 million, exceeding $64.99 million consensus.
- Exome and genome tests revenue grew 77% year-over-year to $60 million.
- Adjusted net income hits $1.2 million, improving 143% sequentially.
- 2024 revenue guidance raised to $284-$290 million, surpassing previous estimates.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.